Back to search results

Comparing PCI and CABG for Diabetes and Multivessel Coronary Artery Disease

This study is comparing two common procedures for treating blocked heart arteries (coronary artery disease) in people with diabetes. It's looking at state-of-the-art Percutaneous Coronary Intervention (PCI), which uses imaging and physiology guidance, versus standard Coronary Artery Bypass Grafting (CABG). The goal is to see which treatment leads to better outcomes, specifically fewer major heart or brain-related events, over two years. You might be able to join if you are at least 20 years old, have angina (chest pain) or signs of heart muscle damage, and have type 2 diabetes requiring treatment or with elevated blood sugar levels. The study plans to enroll 1500 participants, but its current recruitment status is unclear.

Study design
This is a randomized study comparing two different procedures. It plans to enroll 1500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for two years to measure major adverse cardiac or cerebrovascular events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05831085

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

Recruiting
NAAges 20+InterventionalTreatment
Duk-Woo Park, MD
~1,500 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:State-of-the-Art Percutaneous Coronary Interventionstandard CABG

At a glance

Recruiting sites
31 of 39 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The event rate of major adverse cardiac or cerebrovascular events
Measured over 2 years

Conditions

Coronary Artery Stenosis

Explore related trials

Coronary Artery DiseaseDiabetes Mellitus

Where it's being run

39 sites across 14 states
South Korea21
India3
Thailand3
China2
California1
Australia1
Hong Kong1
Japan1

Study leadership

  • Seung-jung Park, MD · STUDY_CHAIR · Asan Medical Center

Who to contact

Jung-hee Ham, Project manager
[email protected]
82-2-3010-4728
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • The event rate of major adverse cardiac or cerebrovascular events2 years

    Major adverse cardiac or cerebrovascular events (MACCE) were defined as a composite of hard clinical endpoints of death from any causes, myocardial infarction, or stroke.